Screener
Amneal Pharmaceuticals, Inc. AMRX Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Amortization of debt issuance costs and discount | 7,954 | 13,686 |
| Reclassification of cash flow hedge | 5,788 | (5,876) |
| Loss on refinancing | 3,510 | — |
| Stock-based compensation | 19,208 | 15,532 |
| Inventory provision | 44,957 | 38,432 |
| Other operating charges and credits, net | 3,086 | 2,254 |
| Changes in assets and liabilities: | ||
| Trade accounts receivable, net | (125,765) | (32,615) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s stock-based comp?
- Amneal Pharmaceuticals, Inc. (AMRX) reported stock-based comp of $10.39M in Q2 2026.
- How has Amneal Pharmaceuticals, Inc.'s stock-based comp changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s stock-based comp increased by 25.6% year-over-year, from $8.27M to $10.39M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s stock-based comp has grown at a 3.0% compound annual growth rate (CAGR), from $28.41M to $31.95M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Amneal Pharmaceuticals, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude